#Canada #Aurora Cannabis #Edmonton #Curaleaf Holdings #EU-GMP

Aurora Cannabis Challenges Curaleaf's Misleading Claims Amid Hostile Takeover Attempt

In a recent press release, Aurora Cannabis Inc. publicly addressed inaccuracies made by Curaleaf Holdings, Inc. regarding their proposed hostile takeover. Curaleaf's portrayal of Aurora's operations appears to serve their own interests, aimed at acquiring Aurora's esteemed EU-GMP certified manufacturing facilities at the lowest possible price, undermining the true value of Aurora's robust operations.

Background to the Hostile Bid

On August 24, 2026, Aurora Cannabis communicated to its shareholders about Curaleaf's unsolicited takeover attempt, characterized as a Hostile Bid. Aurora’s Board of Directors is actively reviewing Curaleaf's proposal with the guidance of independent financial and legal advisors. As of now, shareholders are advised to TAKE NO ACTION until further recommendations are provided.

Miguel Martin, the Executive Chairman and CEO of Aurora, stated, "Curaleaf's timing and public comments appear to be a transparent attempt to pressure Aurora shareholders into making a short-term decision for the benefit of Curaleaf shareholders." This accusation reflects a larger strategy, where Curaleaf aims to acquire Aurora's world-class infrastructure while depriving its shareholders of potential long-term value.

Performance and Growth Opportunities

Aurora is witnessing significant growth with a year-over-year net revenue increase of 17%. This performance is largely driven by their high-margin operations, especially in the German market, which remains pivotal for their international expansion. Contrary to Curaleaf's claims, recent changes in the German medical reimbursement structure have minimal impact on Aurora, as that segment constituted less than 10 percent of their total volume prior to the changes.

Additionally, Aurora is making strides in the UK medical market, bolstered by its acquisitions of Internode Pharma Limited and HAP Pharma Limited, enhancing distribution capabilities in the fastest-growing segment of the European medical cannabis market. In Poland, Aurora maintains a strong market presence, holding the number one position by revenue, which validates the company's growth strategy in this heavily regulated area.

Refuting Curaleaf’s Claims

Aurora’s recent financial successes counter the narrative portrayed by Curaleaf. Notably, Aurora has reached record global medical cannabis revenues and robust adjusted EBITDA in FY2026. Curaleaf's criticisms regarding Aurora's cultivation capabilities have proven outdated; Aurora has built specialized expertise with their EU-GMP-certified production facilities, setting them apart from competitors. The company has scaled its production capacity by over 40% in the last five years to meet rising patient demand while adhering to strict regulatory standards.

The company's response emphasizes accuracy, as Curaleaf's public statements appear to diminish the significance of their ongoing engagement with Aurora. The board's formation of a Special Committee highlights the importance of safeguarding shareholder interests and ensuring that the actual value of Aurora's operations is recognized.

Looking Ahead

As this situation unfolds, shareholders are urged to remain vigilant but calm, refraining from any action until official guidance is issued from Aurora’s Board. For inquiries about the offer or to receive updates, stakeholders can contact Kingsdale Advisors, Aurora's strategic advisor, at various provided communications channels.

In conclusion, while speculative claims and pressure tactics from Curaleaf may cloud the narrative, Aurora Cannabis remains steadfast, focusing on their proven growth strategy and the robust performance of their global cannabis initiatives. The company stands committed to maintaining its value and positioning itself as a frontrunner in the medical cannabis industry as discussions continue.

For the latest updates and information, visit Aurora Cannabis' official website.